Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study is aimed to evaluate the progression-free survival(PFS) and also survival of IP
and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer
and to explore the reasonable first-line therapy for Chinese population. An open-label,
multi-center study will be conducted with dynamic randomization of approximately 1:1 ratio
with an estimation of 308 eligible participants.